Samuel Weisbrod
6Patents
1h-index
9Co-inventors
40Inventor score
Filing activity: Oct 8, 2013 → Mar 27, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10519226B2 | VEGF neutralizing prodrugs for the treatment of ocular conditions | Chemistry; Metallurgy | 5 | Active |
| US11642415B2 | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | Human Necessities | 1 | Active |
| US11298427B2 | Prodrugs comprising a pyroglutamate linker | Human Necessities | 0 | Active |
| US12246070B2 | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | Human Necessities | 0 | Active |
| US10040850B2 | Protecting group comprising a purification tag | Emerging Cross-Sectional Technologies | 0 | Active |
| US11896671B2 | Conjugation method for carrier-linked prodrugs | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.